Ashland Bellefonte Cancer Center

(606) 836-0202

(800) 543-3728 (Toll Free)

Important Notice to Patients Regarding the Coronavirus Outbreak

We remain OPEN to provide care for our patients. For the health of our patients, we are asking for patients to come to their appointments alone, if possible. We are also checking all patients’ temperatures when entering our clinic.

Real People, Real Stories

Bob Matthews of Ashland, KY

Bob Matthews of Ashland chose Doctor Kirti Jain......Read Story

Carla Pauley of Flatwoods, KY

It all started when Carla lost her mother...Read Story

Barbara Hogsten of Westwood, KY

Barbara has had a long battle with multiple medical....Read Story

Deborah McCabe of Ironton, OH
Breast Cancer

“There are 3 parts to cancer – the spiritual part, keeping....Read Story

Sally Lloyd of Ashland, KY
Exterior Squamous Cell Cancer

For almost 2 years Sally thought she had hemorrhoids....Read Story

Homer Waddle of Ironton, OH
Rectal Cancer

Two years ago on New Year's Eve...Read Story

Read Story


Radioimmunotherapy is a new weapon in the fight against cancer. Zevalin is the first Radioimmunotherapy treatment to be approved by the Food and Drug Administration in the treatment of certain types of non-Hodgkins lymphoma.

Zevalin is different in many ways from conventional chemotherapy or external beam radiation therapy.

Radioimmunotherapy is a treatment that uses a radiation source, such as a radioisotope, with a component of the immune system, such as an antibody. Zevalin combines the cell targeting ability of a monoclonal antibody with the additional cell killing ability of a radioactive material called Yttrium-90.

The monoclonal antibody recognizes and attaches to a particular part of a B-Cell, called the CD20 antigen. This process allows Zevalin to specifically target B-cells, therefore destroying malignant NHL B-Cells.

Treatment can be completed within a week on an out-patient basis. This regime is generally well tolerated by the patients and can be given safely and effectively in a community cancer center.